|
|
DRUG INTERACTIONS
No formal interaction studies have been performed. The duration of the period following treatment with AMEVIVE® before one should consider starting other immunosuppressive therapy has not been evaluated.
|
OVERDOSAGE
The highest dose tested in humans (0.75 mg/kg IV) was associated with chills, headache, arthralgia, and sinusitis within one day of dosing. Patients who have been inadvertently administered an excess of the recommended dose should be closely monitored for effects on total lymphocyte count and CD4+ T lymphocyte count.
|
CONTRAINDICATIONS
AMEVIVE® should not be administered to patients with known hypersensitivity to AMEVIVE® or any of its components.
|
REFERENCES
-
Bos JD, Hagenaars C, Das PK, et al. Predominance of "memory" T cells (CD4+, CDw29+) over "na[iuml ]ve" T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res 1989; 281:24-30.
-
Ellis C, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345:248-255.
-
Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157:238-244.
Issued: May/2004
AMEVIVE® (alefacept)
Manufactured by:
BIOGEN, INC.
14 Cambridge Center
Cambridge, MA 02142 USA
©2004 Biogen, Inc. All rights reserved.
1-866-263-8483
U.S. Patents:
4,956,281
5,547,853
5,728,677
5,914,111
5,928,643
6,162,432
Additional U.S. Patents Pending
I63007-2
|
|
|
|
-- advertisement --
|
